# Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants

> **NCT07372703** · PHASE1 · RECRUITING · sponsor: **Vigonvita Life Sciences** · enrollment: 56 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** VV913 1mg group
- **DRUG:** VV913 2mg group
- **DRUG:** VV913 4mg group
- **DRUG:** VV913 8mg group
- **DRUG:** VV913 15mg group
- **DRUG:** VV913 25mg group
- **DRUG:** VV913 40mg group

## Key facts

- **NCT ID:** NCT07372703
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07372703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07372703, "Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07372703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*